INDIANAPOLIS, Feb. 11, 2011 /PRNewswire/ — Eli Lilly and
Company (NYSE:
LLY) today announced that Sue Mahony, currently senior vice
president of human resources and diversity, has been named senior
vice president and president of Lilly Oncology.
In this new role she continues to report to John Lechleiter,
Ph.D., Lilly chairman, president, and CEO, and she remains a member
of the company’s executive committee. Mahony succeeds John H.
Johnson, who resigned last month.
Being promoted into Mahony’s former role is Steve Fry, currently
vice president of human resources for two of Lilly’s business
areas, bio-medicines and emerging markets. Fry now joins Lilly’s
executive leadership team and reports to Lechleiter. Both moves are
effective immediately.
Mahony
“Sue brings a deep understanding of both the scientific and
commercial aspects of our business gained through a broad range of
leadership roles here at Lilly and with other major pharmaceutical
companies,” said Lechleiter. “Lilly has one of the largest
clinical-stage pipelines of potential cancer medicines in the
industry. Sue is a proven leader who will help Lilly make the most
of these incredible opportunities.”
Mahony joined Lilly more than 10 years ago after a decade in
sales and marketing roles in the United Kingdom and Europe in
oncology/hematology and cardiovascular medicine for Amgen,
Bristol-Myers Squibb, and Schering-Plough. She was named general
manager of Lilly Canada in 2008 after roles in global marketing and
new product development, including a leadership role in the
development of Cymbalta®. Mahony was also the Six Sigma leader
for Lilly’s sales and marketing component. She was promoted to the
top human resources role in 2009.
Mahony received her bachelor’s degree and Ph.D. in pharmacy, in
the Cancer Research Campaign Experimental Chemotherapy Group, from
Aston Uni
‘/>”/>
